12:00 AM
Nov 22, 1999
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

ImmunoGen preclinical data

IMGN said that C242-DM1, the murine version of its huC242-DM1/SB-408075 humanized monoclonal antibody combined with the maytansinoid toxin DM1, gave complete tumor regression...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >